BREAKING ADVANCES

1 Highlights from Recent Cancer Literature

FROM THE EDITOR'S CHAIR

3 A Perspective on Cancer as an Abortive Autoimmune Response to Altered-Self
George C. Prendergast

REVIEWS

5 Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk and George J. Weiner

11 Regulation of Epithelial–Mesenchymal Transition through SUMOylation of Transcription Factors
Maria V. Bogachek, James P. De Andrade, and Ronald J. Weigel

PRIORITY REPORT

16 The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients
Nicole M. Warrington, Tao Sun, Jingqin Luo, Robert C. McKinstrey, Patricia C. Parkin, Sara Ganzhorn, Debra Spoljaric, Anne C. Albers, Amanda Merkelson, Douglas R. Stewart, David A. Stevenson, David Viskochil, Todd E. Druley, Jason T. Forys, Karlyne M. Reilly, Michael J. Fisher, Uti Tabori, Jeffrey C. Allen, Joshua D. Schiffman, David H. Gutmann, and Joshua B. Rubin

CLINICAL STUDIES

22 Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

PRÉCIS: Although clinical application of oncolytic viruses as experimental therapies has frequently been challenged on the grounds of efficacy, more recently engineered vectors based on measles virus may offer effective options to treat certain advanced cancers such as metastatic ovarian cancer.

INTEGRATED SYSTEMS AND TECHNOLOGIES

31 A Noninvasive Procedure for Early-Stage Discrimination of Malignant and Precancerous Vocal Fold Lesions Based on Laryngeal Dynamics Analysis
Jakob Unger, Jörg Lohscheller, Maximilian Reiter, Katharina Eder, Christian S. Betz, and Maria Schuster

PRÉCIS: This study offers a proof of concept for a procedure to diagnose most types of laryngeal cancers, possibly helping avoid current invasive diagnostic procedures that are associated with greater time, morbidity, and cost.

MICROENVIRONMENT AND IMMUNOLOGY

40 Akt1 and Akt3 Exert Opposing Roles in the Regulation of Vascular Tumor Growth

PRÉCIS: These findings offer a preclinical proof of concept for the therapeutic utility of treating poorly understood vascular tumors such as angiosarcoma with 56K inhibitors.
Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>Paradoxical Decrease in the Capture and Lymph Node Delivery of Cancer Vaccine Antigen Induced by a TLR4 Agonist as Visualized by Dual-Mode Imaging</td>
<td>Deepak K. Kadayakkara, Michael J. Korrer, Jeff W.M. Bulte, and Hyam I. Levitsky</td>
</tr>
<tr>
<td>62</td>
<td>Tropomodulin 1 Expression Driven by NF-κB Enhances Breast Cancer Growth</td>
<td>Taku Ito-Kureha, Naohiko Roshikawa, Mizuki Yamamoto, Rentaro Sembha, Noritaka Yamaguchi, Tadashi Yamamoto, Motoharu Seiki, and Jun-ichiro Inoue</td>
</tr>
<tr>
<td>73</td>
<td>Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts</td>
<td>Keun-Woo Lee, So-Young Yeo, Chang Ohk Sung, and Seok-Hyung Kim</td>
</tr>
<tr>
<td>86</td>
<td>Intracellular Osteopontin Inhibits Toll-like Receptor Signaling and Impedes Liver Carcinogenesis</td>
<td>Xiaoyu Fan, Chunyan He, Wei Jing, Xuyu Zhou, Rui Chen, Lei Cao, Minhui Zhu, Rongjie Iia, Hao Wang, Yajun Guo, and Jian Zhao</td>
</tr>
<tr>
<td>98</td>
<td>PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar Rhabdomyosarcoma</td>
<td>Verena Thalhammer, Laura A. Lopez-Garcia, David Herrera-Martin, Regina Hecker, Dominik Laubscher, Maria E. Gietsch, Marco Wachtel, Peter Bode, Paolo Nanni, Bernd Blank, Ewa Koscielniak, and Beat W. Schäfer</td>
</tr>
<tr>
<td>111</td>
<td>LASP1 Is a HIF1α Target Gene Critical for Metastasis of Pancreatic Cancer</td>
<td>Tiansuo Zhao, He Ren, Jing Li, Jing Chen, Huan Zhang, Wen Xin, Yan Sun, Lei Sun, Yongwei Yang, Junwei Sun, Xiuchao Wang, Song Gao, Chonghiao Huang, HuaFeng Zhang, Shengyu Yang, and Jiuli Hao</td>
</tr>
<tr>
<td>120</td>
<td>VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells</td>
<td>Matteo Curtarelli, Elisabetta Zulato, Giorgia Nardo, Silvia Valtorta, Giulia Guzzo, Elisabetta Rossi, Giovanni Esposito, Aichi Msaki, Anna Pastó, Andrea Rasola, Luca Persano, Francesco Ciccarese, Roberta Bertorelle, Sergio Todde, Mario Plebani, Henrike Schroen, Stefan Walenta, Wolfgang Mueller-Klieser, Alberto Amadori, Rosa Maria MoreSCO, and Stefano Indraccolo</td>
</tr>
</tbody>
</table>

Molecular and Cellular Pathobiology

Therapeutics, Targets, and Chemical Biology
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Timing of GLA in relation to vaccination impacts the pattern of OT1 cell accumulation. Representative bioluminescent images show site-specific accumulation of OT1 cells in different groups of mice 4 days post hind footpad vaccination. Vaccine-primed T cells accumulated in the draining lymph nodes in mice that received GVAX only or when GLA 24 was given 24 hrs post GVAX. However, when GLA is coadministered with GVAX, a systemic pattern of T-cell accumulation was observed. For details, see article by Kadayakkaza and colleagues on page 51.